GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Shiller PE Ratio

VALN (Valneva SE) Shiller PE Ratio : (As of Mar. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Shiller PE Ratio Historical Data

The historical data trend for Valneva SE's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Shiller PE Ratio Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.77 - - - -

Valneva SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Shiller PE Ratio

For the Biotechnology subindustry, Valneva SE's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Shiller PE Ratio falls into.



Valneva SE Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Valneva SE's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Valneva SE's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.155/119.5600*119.5600
=-0.155

Current CPI (Sep. 2024) = 119.5600.

Valneva SE Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.493 99.860 -0.590
201503 0.303 100.170 0.362
201506 -0.269 100.440 -0.320
201509 -0.157 99.950 -0.188
201512 -0.478 100.040 -0.571
201603 -0.156 100.020 -0.186
201606 -1.034 100.630 -1.229
201609 -0.202 100.340 -0.241
201612 -0.084 100.650 -0.100
201703 -0.043 101.170 -0.051
201706 -0.067 101.320 -0.079
201709 -0.095 101.330 -0.112
201712 -0.118 101.850 -0.139
201803 0.049 102.750 0.057
201806 -0.047 103.370 -0.054
201809 -0.093 103.560 -0.107
201812 0.182 103.470 0.210
201903 0.113 103.890 0.130
201906 -0.181 104.580 -0.207
201909 0.000 104.500 0.000
201912 0.022 104.980 0.025
202003 -0.022 104.590 -0.025
202006 -0.605 104.790 -0.690
202009 -0.966 104.550 -1.105
202012 -0.049 104.960 -0.056
202103 -0.714 105.750 -0.807
202106 -1.470 106.340 -1.653
202109 -3.765 106.810 -4.214
202112 3.977 107.850 4.409
202203 -0.529 110.490 -0.572
202206 -2.833 112.550 -3.009
202209 1.307 112.740 1.386
202212 -0.678 114.160 -0.710
202303 -0.278 116.790 -0.285
202306 -0.260 117.650 -0.264
202309 -0.534 118.260 -0.540
202312 -0.502 118.390 -0.507
202403 0.891 119.470 0.892
202406 -0.366 120.200 -0.364
202409 -0.155 119.560 -0.155

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (NAS:VALN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Valneva SE Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Valneva SE's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE Business Description

Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

From GuruFocus

Valneva SE Annual Shareholders Meeting Transcript

By GuruFocus Research 02-09-2024

Valneva SE at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Valneva SE Analyst Call Transcript

By GuruFocus Research 02-09-2024

Q3 2023 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2024 Valneva SE Earnings Call Transcript

By GuruFocus News 11-08-2024

Full Year 2022 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Half Year 2020 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Nine Months 2019 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024